phase readout
saveNCT07463768: Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
NOT_YET_RECRUITINGupdated 5mo ago
community read0 votes
Sponsor: French Innovative Leukemia Organisation. Phase: PHASE2. Conditions: Acute Myeloid Leukemia
view source ↗Data sources
last refreshed just now
Found something off?
same company · ±60 days · 6
- phase 1 initiationnavlimetostat: Bristol-Myers Squibb Co — navlimetostat (Phase I Trial Initiation)Apr 30, 2026
- approvalONUREG (AZACITIDINE) — FDA approvalApr 9, 2026
- approvalKRAZATI (ADAGRASIB) — FDA approvalMar 25, 2026
- approvalSOTYKTU (DEUCRAVACITINIB) — FDA approvalMar 6, 2026
- device 510kLiofilchem s.r.l. — MTS Aztreonam-Avibactam 0.016/4 - 256/4 µg/mL (510k cleared)Oct 2, 2025
- device 510kBeckman Coulter, Inc. — MicroScan Dried Gram-Negative MIC/Combo Panels with Aztreonam (AZT) (0.5-64 µg/mL) (510k cleared)Jul 18, 2025
related news · 2
🐶 often sniffed alongside
top 8- drugOPDIVO12 co-mentions · 6 sources
- drugOPDIVO QVANTIG12 co-mentions · 6 sources
- drugnivolumab12 co-mentions · 6 sources
- tagApproval10 co-mentions · 5 sources
- tagOncology9 co-mentions · 1 sources
- drug(hyaluronidase (recombinant, human) + nivolumab)5 co-mentions · 5 sources
- tagNSCLC2 co-mentions · 1 sources
- tagGlioblastoma2 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that